Starnberg

Researchers are evaluating whether systematic pelvic and para-aortic lymphadenectomy LNE improves overall survival in patients with stage I or II endometrial cancer who have a high risk of recurrence. The trial also looks at how LNE affects disease-free survival, quality of life, complications, side effects, and the number of lymph nodes removed. A total of 640 patients with specific histological types and stages of endometrial cancer will take part in this study. Participants will be randomly assigned to one of two groups. In Arm A, patients will undergo the standard surgical procedure including total hysterectomy and bilateral salpingo-oophorectomy, with an omentectomy added for certain cancer types. In Arm B, patients will receive the same standard surgery plus systematic pelvic and para-aortic lymphadenectomy reaching up to the left renal vein. The study compares these two surgical approaches. Throughout the study, participants will be monitored for overall survival over 60 months. Researchers will also assess disease-free and disease-specific survival at multiple time points up to five years. Serious complications will be recorded during surgery and follow-up visits. Quality of life will be evaluated regularly using standardized questionnaires. The number of lymph nodes removed will be documented during surgery to support the evaluation of treatment impact and safety.

Researchers are conducting a prospective, non-interventional, single-arm study called PETRICHOR in Germany to evaluate real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps CRSwNP. The study focuses on patients whose disease is not well controlled by systemic corticosteroids or surgery and who are newly starting treatment with tezepelumab as part of routine clinical care. Treatment decisions are made by patients and their doctors independently of the study, and the study aims to observe outcomes without adding extra diagnostic or monitoring procedures. Participants receive subcutaneous tezepelumab in accordance with approved guidelines for CRSwNP. The study does not intervene but collects data during routine clinical visits over a period of up to 104 weeks. Treatment and monitoring follow usual clinical practice, with no additional procedures required by the study protocol. During the study, participants attend routine clinical visits where researchers collect data on symptom changes and quality of life using tools like the SNOT-22 questionnaire, smell tests, nasal endoscopy, and patient-reported measures. The study also tracks corticosteroid use, response rates, and safety events over two years. Data collection occurs at baseline and regularly during routine care visits to understand treatment outcomes and disease control in a real-world setting.